Acción MGTA MAGENTA THERAPEUTICS
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Magenta Therapeutics

Acciones

MGTA

US55910K1088

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
21,5 USD +2,43 % Gráfico intradía de Magenta Therapeutics -7,53 % +92,07 %
2023 Dianthus Therapeutics, Inc. completó la adquisición de Magenta Therapeutics, Inc. (NasdaqGM:MGTA) a un grupo de accionistas en una transacción de fusión inversa. CI
2023 Magenta Therapeutics, Inc. presenta los resultados del segundo trimestre y los seis meses finalizados el 30 de junio de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Adrenoleukodystrophy Clinical Trials, and Key Companies|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others
Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index
Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.
North American Morning Briefing : PCE Inflation -2-
North American Morning Briefing : Nasdaq Futures -2-
North American Morning Briefing : Treasury Yields Keep Pushing Higher
North American Morning Briefing : Attention Turns -2-
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index
Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer
Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
North American Morning Briefing : Hopes Build for -3-
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción MGTA
  4. Noticias Magenta Therapeutics
  5. Otros idiomas